Andrew Polovin Sells 7,927 Shares of Tempus AI (NASDAQ:TEM) Stock

Posted by Brian Himes on Aug 20th, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) EVP Andrew Polovin sold 7,927 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $56.00, for a total transaction of $443,912.00. Following the completion of the transaction, the executive vice president owned 138,140 shares of the company’s stock, valued at approximately $7,735,840. The trade was a 5.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28.

Tempus AI Stock Up 8.8%

NASDAQ:TEM traded up $5.40 during midday trading on Thursday, hitting $66.65. 20,103,049 shares of the company were exchanged, compared to its average volume of 5,600,288. The company has a fifty day simple moving average of $52.44 and a 200 day simple moving average of $51.21. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the previous year, the company earned ($0.22) earnings per share. Tempus AI’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, equities analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wolfe Research began coverage on Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. HC Wainwright reduced their price objective on Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. BTIG Research increased their price objective on Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $65.69.

Get Our Latest Research Report on TEM

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the third quarter worth approximately $26,000. Los Angeles Capital Management LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI in the 3rd quarter valued at $38,000. Whittier Trust Co. increased its stake in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Tempus AI by 88.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock valued at $44,000 after buying an additional 325 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.